NDA 208010 · Eirgen
Rayaldee
Calcifediol · Oral
Last checked: Nov 19, 2026Latest source record: Jan 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jun 17, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
61
19 Phase 3, 3 recruiting
FAERS reports
2,547
2,435 serious, 384 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 19, 2024.
RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Limitations of Use RAYALDEE is not indicated for the treatment of secondary hyperparathyroidism in patients with stage 5 chronic kidney disease or in patients with end-stage renal disease on dialysis. RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. ( 1 ) Limitations of Use: RAYALDEE is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis. ( 1 )
Mechanism: Calcifediol (25-hydroxyvitamin D 3 ) is a prohormone of the active form of vitamin D 3 , calcitriol (1,25‑dihydroxyvitamin D 3 ). Calcifediol is converted to calcitriol by cytochrome P450 27B1 (CYP27B1), also called 1-alpha hydroxylase, primarily in the kidney. Calcitriol binds to the vitamin D receptor in target tissues and activates vitamin D responsive pathways that result in increased intestinal absorption of calcium and phosphorus and reduced parathyroid hormone synthesis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 17, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewSummary Review
1 products under this application
- RAYALDEE · CALCIFEDIOL 0.03MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Calcifediol" as an intervention, any sponsor and status, largest first.
- Oral 25-hydroxyvitamin D3 and COVID-19Pivotal-lookingStatus unknown
Tehran University of Medical SciencesAcademic, hospital or other
NCT04386850 · 1,500 participants (planned) · Start Apr 14, 2020 · Primary completion Nov 15, 2020
Drug: Oral 25-Hydroxyvitamin D3 · For: COVID 19
Sites: Tehran, Iran
- Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D DeficiencyPivotal-lookingCompleted
Faes Farma, S.A.Industry
NCT04735926 · 674 participants · Start Dec 23, 2020 · Primary completion Jul 21, 2022
Drug: Calcifediol 75mcg; Calcifediol 100mcg and 1 more · For: Vitamin D Deficiency; Vitamin D Insufficiency
Sites: Sevlievo, Bulgaria; Sofia, Bulgaria; Brno, Czechia · 55 sites in all
- Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory SyndromePivotal-lookingCompleted
Maimónides Biomedical Research Institute of CórdobaAcademic, hospital or other
NCT04366908 · 517 participants · Start May 7, 2020 · Primary completion Apr 19, 2022
Drug: BAT + Calcifediol; BAT · For: SARS-CoV 2; COVID19; SARS (Severe Acute Respiratory Syndrome) and 2 more
Sites: Córdoba, Spain
- The Effect of Vitamin D Supplementation on Cardiovascular Risk FactorsPivotal-lookingCompleted
University of TromsoAcademic, hospital or other
NCT02750293 · 411 participants · Start Jun 2015 · Primary completion Aug 2017
Drug: Cholecalciferol; Placebo · For: Vitamin D Deficiency
Sites: Tromsø, Norway
- Association Between Vitamin D and the Development of Uterine FibroidsPivotal-lookingStatus unknown
Second Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT03584529 · 360 participants (planned) · Start Sep 15, 2018 · Primary completion Jan 1, 2021
Drug: Vitamin D 3 · For: Gynaecological Disease; Vitamin D Deficiency
Sites: Wenzhou, China
- Vitamin D Supplementation and Male Infertility: The CBG-study a Randomized Clinical TrialPivotal-lookingCompleted
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT01304927 · 307 participants · Start Feb 2011 · Primary completion Dec 2014
Drug: Cholecalciferol and calcium · For: Male Infertility
Sites: Copenhagen, Denmark
- Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002Pivotal-lookingCompleted
OPKO Health, Inc.Industry
NCT02282813 · 298 participants · Start Apr 2013 · Primary completion May 2015
Drug: CTAP101 Capsules; Calcitriol and 2 more · For: Chronic Kidney Disease; Hyperparathyroidism, Secondary; Vitamin D Deficiency
- Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyPivotal-lookingCompleted
OPKO IP Holdings II, Inc.Industry
NCT01704079 · 216 participants · Start Nov 2012 · Primary completion Aug 2014
Drug: CTAP101 30 μg capsules · For: Chronic Kidney Disease; Hyperparathyroidism, Secondary; Vitamin D Deficiency
Sites: Bannockburn, Illinois
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death219
- off label use141
- drug interaction131
- acute kidney injury127
- anaemia78
- nausea76
- dyspnoea74
- pneumonia70
- pyrexia70
- covid-1964
- hypotension63
- diarrhoea62
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 5 |
| 2010 | 12 |
| 2011 | 2 |
| 2012 | 10 |
| 2013 | 7 |
| 2014 | 9 |
| 2015 | 11 |
| 2016 | 15 |
| 2017 | 40 |
| 2018 | 79 |
| 2019 | 122 |
| 2020 | 158 |
| 2021 | 166 |
| 2022 | 267 |
| 2023 | 392 |
| 2024 | 494 |
| 2025 | 358 |
| 2026 | 384 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rayaldee (Calcifediol)
2024 spending
$42.8M
Beneficiaries
5,248
31,494 claims
Per beneficiary
$8,164
$40.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $61,315,676 |
| 2021 | $39,639,508 |
| 2022 | $36,135,698 |
| 2023 | $41,491,958 |
| 2024 | $42,845,344 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Infections and Autoimmunity-The Immune System and Vitamin D: A Systematic Review.
Wimalawansa SJ · Nutrients 2023 · Systematic Review
- Effect of calcifediol and cholecalciferol on muscle function in postmenopausal women: a randomized controlled trial.
Bischoff-Ferrari HA, Dawson-Hughes B, Orav JE, et al. · Osteoporos Int 2025 · Randomized Controlled Trial
- REsCue trial: Randomized controlled clinical trial with extended-release calcifediol in symptomatic COVID-19 outpatients.
Bishop CW, Ashfaq A, Melnick JZ, et al. · Nutrition 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Randomized Controlled Trial for the Effect of Vitamin D Supplementation on Vascular Stiffness in CKD.
Levin A, Tang M, Perry T, et al. · Clin J Am Soc Nephrol 2017 · Randomized Controlled Trial
- Effect of Calcifediol on Physical Performance and Muscle Strength Parameters: A Systematic Review and Meta-Analysis.
Barbagallo M, Veronese N, Di Prazza A, et al. · Nutrients 2022 · Meta-Analysis, Systematic Review
- Effect of vitamin D3 vs. calcifediol on VDR concentration and fiber size in skeletal muscle.
Ceglia L, Rivas DA, Schlögl M, et al. · J Bone Miner Metab 2023 · Randomized Controlled Trial
Sponsor: Eirgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.